Bill Roegge

Cooley advised Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, on its successful proxy contest against Deep Track Capital.

Cooley advised Heliogen, a provider of on-demand clean energy technology solutions, on its definitive agreement with Zeo Energy, a Florida-based provider of residential solar and energy efficiency solutions, representing the culmination of Heliogen’s review of strategic alternatives and pursuant to which Zeo will acquire all of Heliogen’s outstanding equity securities in an all-stock transaction.

Cooley advised Araris Biotech, a Swiss biotechnology company developing next-generation antibody-drug conjugates, on its definitive agreement to be acquired by Japan-based Taiho Pharmaceutical for up to $1.14 billion in cash.

Cooley advised the special committee of Checkpoint Therapeutics’ (Nasdaq: CKPT) board of directors in connection with Checkpoint’s definitive agreement to be acquired by Sun Pharmaceutical Industries (NSE: SUNPHARMA) for up to $416 million in cash and contingent value rights.

Cooley advised Katy Hearn and Haydn Schneider, co-founders of Alani Nu, in connection with Celsius Holdings’ (Nasdaq: CELH) definitive agreement to acquire the company for $1.8 billion in cash and stock.